申请人:Bayer Aktiengesellschaft
公开号:EP3822268A1
公开(公告)日:2021-05-19
The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty.
R 1 is hydrogen, alkyl, cycloalkyl, 5- to 6-membered heterocycloalkyl, 5- to 10-membered heteroaryl or phenyl; R 2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R 3 , R 4 , R 5 , R 6 , R 7 , R 8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R 2 , R 3 , R 4 is H; X 1 , X 2 , X 3 , X 4 , X 5 , X 6 are independently N or C; with the proviso that in each ring maximal one X is N.
本申请涉及作为 ADAMTS7 拮抗剂的式 (I) 取代的 hydantoinamides、其制备工艺、单独使用或联合使用以治疗或预防疾病,特别是心血管疾病,包括动脉粥样硬化、冠状动脉疾病 (CAD)、外周血管疾病 (PAD)、动脉闭塞性疾病或血管成形术后再狭窄。
R 1 是氢、烷基、环烷基、5-6 元杂环烷基、5-10 元杂芳基或苯基;R 2 是氢、氰基、卤素、烷基磺酰基、烷基、环烷基或烷氧基;R 3、R 4、R 5、R 6、R 7、R 8 独立地是氢、卤素、烷基或烷氧基;X1、X2、X3、X4、X5、X6 独立地为 N 或 C,但每个环中最多一个 X 为 N。